Immune profiling in a randomized phase II trial of acalabrutinib and pembrolizumab (PA) versus pembrolizumab (P) for patients with metastatic urothelial cancer (mUC)

被引：0
|
作者：
Zhang, Tian
Staats, Janet S.
Chan, Cliburn
Harrison, Michael Roger
O'Donnell, Peter H.
Batich, Kristen A.
Chen, Tianling
Krejsa, Cecile
Izumi, Raquel
George, Daniel J.
Weinhold, Kent J.
机构：
[1] Duke Univ, Med Ctr, Durham, NC USA
[2] Duke Univ, Duke Canc Inst, Med Ctr, Durham, NC USA
[3] Univ Chicago, Comprehens Canc Ctr, Chicago, IL 60637 USA
[4] ICON Dev Soult, Palo Alto, CA USA
[5] Acerta Pharma, Redwood City, CA USA
[6] Duke Univ, Durham, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.4533
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4533
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer
    Zhang, Tian
    Harrison, Michael R.
    O'Donnell, Peter H.
    Alva, Ajjai S.
    Hahn, Noah M.
    Appleman, Leonard J.
    Cetnar, Jeremy
    Burke, John M.
    Fleming, Mark T.
    Milowsky, Matthew, I
    Mortazavi, Amir
    Shore, Neal
    Sonpavde, Guru P.
    Schmidt, Emmett, V
    Bitman, Bojena
    Munugalavadla, Veerendra
    Izumi, Raquel
    Patel, Priti
    Staats, Janet
    Chan, Cliburn
    Weinhold, Kent J.
    George, Daniel J.
    CANCER, 2020, 126 (20) : 4485 - 4497
  • [2] Phase 2 study of pembrolizumab alone or combined with acalabrutinib in platinum-refractory metastatic urothelial carcinoma (mUC)
    Zhang, T.
    Harrison, M.
    O'Donnell, P.
    Alva, A.
    Hahn, N.
    Appleman, L. J.
    Cetnar, J.
    Burke, J.
    Fleming, M.
    Milowsky, M.
    Mortazavi, A.
    Shore, N.
    Schmidt, E. V.
    Kresja, C.
    Chen, T.
    Bitman, B.
    Izumi, R.
    Hamdy, A.
    George, D. J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [3] Multidimensional flow characterization of circulating immune cells in cisplatin-resistant metastatic urothelial cancer (mUC) patients (pts) treated with pembrolizumab (P) with or without acalabrutinib (acala).
    Zhang, Tian
    Staats, Janet S.
    Chan, Cliburn
    Alva, Ajjai Shivaram
    O'Donnell, Peter H.
    Harrison, Michael Roger
    Batich, Kristen A.
    Munugalavadla, Veerendra
    George, Daniel J.
    Weinhold, Kent J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [4] Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma
    Sundahl, Nora
    Vandekerkhove, Gillian
    Decaestecker, Karel
    Meireson, Annabel
    De Visschere, Pieter
    Fonteyne, Valerie
    Daan De Maeseneer
    Reynders, Dries
    Goetghebeur, Els
    Van Dorpe, Jo
    Verbeke, Sofie
    Annala, Matti
    Brochez, Lieve
    van der Eecken, Kim
    Wyatt, Alexander W.
    Rottey, Sylvie
    Ost, Piet
    EUROPEAN UROLOGY, 2019, 75 (05) : 707 - 711
  • [5] Phase 1 trial of pembrolizumab with SBRT in metastatic urothelial carcinoma
    Sundahl, N.
    Rottey, S.
    Decaestecker, K.
    De Visschere, P.
    De Maeseneer, D.
    Reynders, D.
    Meireson, A.
    Goetghebeur, E.
    Fonteyne, V.
    Verbeke, S.
    Brochez, L.
    Ost, P.
    RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S357 - S358
  • [6] Phase II (INSPIRE) trial of pembrolizumab (pembro) with serial immune and genomic profiling in patients (pts) with metastatic triple negative breast cancer (mTNBC).
    Veitch, Zachary William Neil
    Cescon, David W.
    Elston, Sawako
    Lien, Scott
    Yang, Cindy
    Wang, Ben X.
    Berman, Hal K.
    Butler, Marcus O.
    Amir, Eitan
    Elser, Christine
    Hakgor, Sevan
    Giesler, Amanda
    Pugh, Trevor John
    Ohashi, Pamela S.
    Siu, Lillian L.
    Bedard, Philippe L.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] Phase II trial of pembrolizumab (P) in combination with sEphB4-HSA (B4) in previously treated metastatic urothelial carcinoma (mUC)
    Sadeghi, S.
    Quinn, D. I.
    Dorff, T.
    Pal, S. K.
    Groshen, S.
    Tsao-Wei, D.
    Lara, P. N.
    Parikh, R.
    Devitt, M. E.
    Parikh, M.
    Jackovich, A.
    Vogelzang, N. J.
    Burgess, E. F.
    Dreicer, R.
    Siddiqi, I.
    Gill, I.
    Gill, P.
    ANNALS OF ONCOLOGY, 2021, 32 : S678 - S678
  • [8] Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial
    Siefker-Radtke, A. O.
    Matsubara, N.
    Park, S. H.
    Huddart, R. A.
    Burgess, E. F.
    Ozguroglu, M.
    Valderrama, B. P.
    Laguerre, B.
    Basso, U.
    Triantos, S.
    Akapame, S.
    Kean, Y.
    Deprince, K.
    Mukhopadhyay, S.
    Loriot, Y.
    ANNALS OF ONCOLOGY, 2024, 35 (01) : 107 - 117
  • [9] Phase Ib/II trial of lenvatinib plus pembrolizumab in urothelial cancer.
    Vogelzang, Nicholas J.
    Encarnacion, Carlos A.
    Cohn, Allen Lee
    DiSimone, Christopher
    Rasco, Drew W.
    Richards, Donald A.
    Taylor, Matthew H.
    Dutcus, Corina E.
    Stepan, Daniel E.
    Shumaker, Robert Charles
    Guo, Matthew
    Schmidt, Emmett V.
    Mier, James Walter
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [10] A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer
    Rijnders, Maud
    Robbrecht, Debbie G. J.
    Oostvogels, Astrid A. M.
    van Brakel, Mandy
    Boormans, Joost L.
    Aarts, Maureen J. B.
    Balcioglu, Hayri E.
    Hamberg, Paul
    Voortman, Jens
    Westgeest, Hans M.
    Lolkema, Martijn P.
    de Wit, Ronald
    van der Veldt, Astrid A. M.
    Debets, Reno
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (03) : 759 - 767
12345